arrow
I

Ivan Moiseev

Pavlov First Saint Petersburg State Medical University
H指数:20
被引数:1,496

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lung transplantation after allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT

同种异基因造血干细胞移植后的肺移植:EBMT移植并发症工作组的研究

2026-10-260
PRE
GvHD prophylaxis in elderly patients: post-transplant cyclophosphamide or ATG? A study by the EBMT transplant complications working party

老年患者移植排斥反应预防:移植后环磷酰胺还是抗胸腺细胞球蛋白?EBMT移植并发症工作组研究

2026-10-060
PRE
Allogeneic Stem Cell Transplantation—A Salvage Option for High-Risk Chronic Lymphocytic Leukemia Patients: A 15-Year Single-Center Experience

异基因干细胞移植——高风险慢性淋巴细胞白血病患者的一种挽救性选择:一项15年单中心经验

2026-08-200
PRE
Fecal microbiota transplantation in the treatment of acute graft-versus-host disease: A retrospective study performed by the Complications Working Party and Pediatric Diseases Working Party of the EBMT

粪菌移植在急性移植物抗宿主病治疗中的应用:EBMT并发症工作组与儿科疾病工作组开展的一项回顾性研究

2026-08-180
PRE
A randomized, multicenter Phase II trial to compare prophylaxis of graft versus host disease with tacrolimus and mycophenolate mofetil versus ruxolitinib after post-transplant cyclophosphamide

一项随机、多中心II期临床试验,比较他克莫司和霉酚酸吗啉乙酯与鲁索利替尼预防移植物抗宿主病的效果,该试验在移植后环磷酰胺治疗基础上进行

2026-04-300
PRE
The discovery of novel AKT inhibitor (4-(purin-6-yl)piperazin-1-yl)(benzofuran-2-yl)methanone for treatment of myeloid neoplasms: Computer modelling, synthesis and biological activity

新型AKT抑制剂(4-(嘌呤-6-基)哌嗪-1-基)(苯并呋喃-2-基)甲酮用于治疗髓系肿瘤的发现:计算机建模、合成及生物活性

2026-02-150
PRE
Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide—A Prospective Study on Behalf of the EBMT Transplant Complications Working Party

haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide的并发症——EBMT移植并发症工作组发起的一项前瞻性研究

2025-12-180
OAAI
Five-Year Follow-Up of Patients With Relapsed and Refractory Classic Hodgkin Lymphoma Treated With Low-Dose Nivolumab (40 mg): A Matched Cohort Study With Standard-Dose Therapy

低剂量纳武利尤单抗(40 mg)治疗复发和难治性经典霍奇金淋巴瘤患者的五年随访:一项与标准剂量疗法匹配的队列研究

2025-10-110
PRE
Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party

使用rATG/ATLG时,匹配同胞供者 allo-HCT 的无GVHD无复发生存率得到改善——EBMT移植并发症工作组登记研究

2025-09-110
PRE
Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMT

移植后环磷酰胺和抗胸腺细胞球蛋白在8/10 HLA错配无关供者移植中的应用:欧洲血液和骨髓移植学会移植并发症工作组的分析

2025-08-190
PRE
Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working party

慢性移植物抗宿主病30年趋势研究——EBMT移植并发症工作组的研究

2025-08-190
PRE
Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party

达鲁atumumab治疗造血干细胞移植后纯红细胞再生障碍:EBMT移植并发症工作组的研究与实践考量

2025-06-040
OAAI
An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy

ASTCT、CIBMTR、EBMT和APBMT关于造血细胞移植相关血栓性微血管病(TA-TMA)导向治疗反应标准的共识声明

2025-06-010
OAAI
Allogeneic hematopoietic cell transplantation with a combination of posttransplantation bendamustine and cyclophosphamide in refractory myeloid neoplasms

异基因造血细胞移植联合移植后 bendamustine 和 cyclophosphamide 治疗难治性髓系肿瘤

CANCER
IF5.1
2025-05-150
PRE
The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT

ABO配型对异基因造血细胞移植结局的影响:欧洲血液和骨髓移植协会移植并发症工作组的一项当代综合性研究

2025-04-170
PRE
Time course of organ and hematological response to complement blockage in transplant-associated thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation

同种异基因造血干细胞移植后移植相关血栓性微血管病中,器官和血液学对补体阻断的反应时间进程

2025-03-270
OA
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study
LEUKEMIA
IF13.4
2024-11-190
PRE
Practice Patterns of SGLT2 Inhibitor Use in Stem Cell Transplantation and CART Cell Therapy: A Study from the EBMT Transplant Complications Working Party

SGLT2抑制剂在干细胞移植和CART细胞治疗中的使用模式:EBMT移植并发症工作组的研究

BLOOD
IF23.1
2024-11-050
PRE